Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Moderna, Inc. (MRNA)

150.02   -1.76 (-1.16%) 03-17 16:00
Open: 151.92 Pre. Close: 151.78
High: 154.45 Low: 149.1
Volume: 5,991,451 Market Cap: 57,959(M)

Technical analysis

as of: 2023-03-20 8:47:55 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 187.66     One year: 207.16
Support: Support1: 133.66    Support2: 111.2
Resistance: Resistance1: 160.67    Resistance2: 177.36
Pivot: 143.14
Moving Average: MA(5): 150.11     MA(20): 145.94
MA(100): 171.24     MA(250): 156.4
MACD: MACD(12,26): -5.2     Signal(9): -7.6
Stochastic oscillator: %K(14,3): 76.4     %D(3): 68.6
RSI: RSI(14): 46.5
52-week: High: 217.25  Low: 115.02
Average Vol(K): 3-Month: 4,070 (K)  10-Days: 3,584 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MRNA ] has closed below upper band by 18.3%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 154.68 - 155.46 155.46 - 156.1
Low: 147.33 - 148.14 148.14 - 148.81
Close: 148.83 - 150.1 150.1 - 151.15

Company Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 15 Mar 2023
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research

Tue, 14 Mar 2023
Moderna Announces Phase 2 Data on mRNA-4157/V940, an ... - Yahoo Finance

Tue, 14 Mar 2023
TD Cowen Upgrades Moderna (MRNA) - Nasdaq

Mon, 13 Mar 2023
Should You Buy Moderna Inc (MRNA) Stock After it Is Higher By 0.90% in a Week? - InvestorsObserver

Fri, 10 Mar 2023
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023 - Yahoo Finance

Thu, 02 Mar 2023
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 384 (M)
Shares Float 347 (M)
% Held by Insiders 9.6 (%)
% Held by Institutions 67.9 (%)
Shares Short 14,130 (K)
Shares Short P.Month 14,040 (K)

Stock Financials

EPS -1.97
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.42
Profit Margin (%) 55
Operating Margin (%) 61.9
Return on Assets (ttm) 35.2
Return on Equity (ttm) 83.6
Qtrly Rev. Growth -32.3
Gross Profit (p.s.) 36.07
Sales Per Share 55.67
EBITDA (p.s.) 35.4
Qtrly Earnings Growth -67.1
Operating Cash Flow 6,630 (M)
Levered Free Cash Flow 3,780 (M)

Stock Valuations

PE Ratio -76.55
PEG Ratio -0.2
Price to Book value 23.36
Price to Sales 2.69
Price to Cash Flow 8.69

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.